|Budget Amount *help
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|Outline of Final Research Achievements
The renin-angiotensin system (RAS) plays pivotal roles in homeostasis, but its abnormal activation has been proposed as a risk factor for several disorders including diabetes. Using animal models, we previously clarified the molecular mechanisms in which tissue RAS stimulates retinal angiogenesis and the critical roles of (pro)renin receptor [(P)RR] in retinal RAS activation and its concurrent intracellular signal transduction, i.e., the receptor-associated prorenin system (RAPS). RAPS is involved in the pathogenesis of several ocular disorders. However, its physiological functions remain unclear. The goal of this study is to develop a novel agent which can inhibit (P)RR functions, and determine its safety and efficacy in vitro and in vivo.